Glofitamab, sold under the brand name Columvi, is a bispecific monoclonal antibody used for the treatment of large B-cell lymphoma.
[7] The most common side effects include cytokine release syndrome, muscle and bone pain, rash, and tiredness.
[8][15] Glofitamab is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
[11] The US Food and Drug Administration (FDA) label includes a boxed warning for serious or fatal cytokine release syndrome.
[11] The trial was conducted at 32 sites in 13 of countries in Australia, Belgium, Canada, Czech Republic, Denmark, Spain, Finland, France, Italy, New Zealand, Poland, Taiwan, and the United States.